EBITDA dipped 1.4% to ₹580 crore in the first quarter compared to ₹588.2 crore a year ago. The EBITDA margin was lower at 17.7% versus 18.1% in Q1FY25. Shares of Glenmark Pharmaceuticals Ltd ended at ₹2,038.95, up by ₹7.15 or 0.35%, on the BSE today (August 14).
